tear meniscus height after BTX-A injection in the medial portion, thereby improving dry eye. Additionally, the methodology of tear meniscus area calculation needs further explanation, as the markings in the figure seem to depict tear meniscus height rather than tear meniscus area. The study mentions variations in the total dose of BTX-A applied, ranging from 32.5 units to 50 units. Given the varied protocols followed by clinicians pertaining to injection sites, dosages, and techniques, it is essential to explore whether these variations contributed to the reported differences in tear film changes. Moreover, the concentration of botulinum toxin used may have played a significant role in the observed outcomes, and it would be helpful to understand the implications of these differences. Any correlation between the dose of BTX-A with surface metrics and injection sites with surface metrics would add value to the current study. In conclusion, while the study contributes useful insights into the impact of BTX-A on ocular surface metrics, addressing these concerns and providing additional details would enhance the robustness and clarity of the study.